Skip to content

Research on the Clinical Value of AKR1B10 in the Stratified Diagnosis of Pancreatic Cancer and Precancerous Lesions

Research on the Clinical Value of AKR1B10 in the Stratified Diagnosis of Pancreatic Cancer and Precancerous Lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109226
Enrollment
Unknown
Registered
2025-09-15
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PDAC

Interventions

High-Risk Benign Lesion Group:None
Low-Risk Benign Lesion Group:None
Healthy Control Group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age for both men and women: = 18 years old, <=80 years old; 2. Be willing to participate in this research project and sign the informed consent form; 3. Pancreatic Cancer group: Pathologically confirmed PDAC (stage I-IV); High-risk benign lesion group: IPMN(intraductal papillary mucinous neoplasm of the pancreas), MCN(mucinous cystic neoplasm), chronic pancreatitis; Low-risk benign lesion group: serous cystadenoma (SCN), simple cyst; Healthy control group: No pancreatic diseases, no liver and gallbladder diseases, and no malignant tumors.

Exclusion criteria

Exclusion criteria: 1.Patients who are pregnant or lactating. 2.Patients with incomplete clinical data, serological test results, or imaging findings. 3.Patients with severe concomitant systemic diseases (e.g., cardiac, cerebral, pulmonary, renal, or hematopoietic systems) or other malignancies.

Design outcomes

Primary

MeasureTime frame
AKR1B10;

Countries

China

Contacts

Public ContactHao Zhang

West China Hospital, Sichuan University

zhanghaohuaxi@163.com+86 189 8060 5218

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026